Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Costs, Cognitive Abilities and Quality of Life After Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement (CCQ)

11. november 2016 oppdatert av: Francesco Saia, MD, PhD, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Multicenter, prospective, observational study in aortic stenosis (AS) patients undergoing transcatheter aortic valve implantation (TAVI) or high-risk patients undergoing aortic valve replacement (AVR).

The objectives of the study are:

  1. Description of neurocognitive status before and after transcatheter aortic valve implantation and aortic valve replacement procedures
  2. Description of Quality of Life (QoL) after these procedures
  3. Defining the relevance of baseline psychological, emotional and cognitive factors on the outcomes associated to the different treatment modalities
  4. Assessment of costs associated to each of the above mentioned strategies of treatment, including costs of the index hospitalization and costs of follow-up.

Studieoversikt

Detaljert beskrivelse

In Italy, a nation-wide observational study endorsed by the Superior Institute of Health has been previously launched in order to evaluate appropriateness and effectiveness of aortic valve replacement (AVR) and transcatheter aortic valve implantation (TAVI) procedures: the OBservational Study of Effectiveness of AVR-TAVI procedures for severe Aortic steNosis Treatment (OBSERVANT). The present study was designed to complement the national survey on TAVI and AVR procedures including data about costs, cognitive functions and quality of life after these procedures. This integrated framework may help defining the relevance of baseline psychological, emotional and cognitive factors on the outcomes associated to the different treatment modalities and, on the other hand, should enable accurate evaluation of the impact of each kind of treatment on quality of life and neuropsychological functions. These elements could also represent relevant keys to decision-making to the different therapeutic strategies. In addition, we aim to ascertain costs associated to each of the above mentioned strategies of treatment, including costs of the index hospitalization and follow-up costs. Costs estimate, combined to the integrated physical and mental health status outcome for each treatment modality, may represent the background for subsequent cost-effectiveness analyses.

All consecutive patients undergoing transcatheter aortic valve implantation or aortic valve replacement (if age ≥ 80 years or Logistic Euroscore ≥ 15%) for aortic stenosis at participating centers during the period of enrollment will be included in the registry, after release of written informed consent. Allocation of patients to different treatment groups will be performed jointly by a cardiologist and a cardiac surgeon on the basis of a complete clinical framework, independently from the present study and in accordance with available guidelines. Type of treatment (for example, access site for TAVI, type of prosthesis…) will be decided by the physicians based on local clinical practice and general principles of good clinical practice.

The administration of neurocognitive and quality of life questionnaires will be performed before the procedure and after 3 months and 1 year by trained personnel following standard operation procedures defined by a coordinating unit. A telephone and web-based support for operators will be available throughout the entire duration of the study. A common methodology for data collection and analysis is defined to guarantee data reliability and homogeneity of assessments among the participating units. The cost analysis will be coordinated by the Regional Healthcare and Social Agency of the Emilia Romagna Region.

Data will be collected in a web-based database (OBSERVANT) through dedicated Case Records Forms and a final database will be built by merging this database with a separate database for costs and Hospital Discharge Records and Mortality Registry databases.

Studietype

Observasjonsmessig

Registrering (Faktiske)

518

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Bologna, Italia, 40138
        • Institute of Cardiology, Azienda Ospedaliero-Universitaria di Bologna

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

All consecutive patients undergoing TAVI or AVR for AS at participating centers during the period of enrollment

Beskrivelse

Inclusion Criteria:

  • All consecutive patients undergoing TAVI at participating centers during the period of enrollment
  • All consecutive patients aged ≥80 years or with Logistic Euroscore ≥15% undergoing AVR at participating centers during the period of enrollment

Exclusion Criteria:

  • Absence of informed consent

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: Kohort
  • Tidsperspektiver: Potensielle

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Transcatheter aortic valve implantation
All consecutive patients undergoing TAVI at participating centres during study period
Patients undergoing TAVI with transfemoral, transapical, or any other vascular access
Andre navn:
  • Edwards Sapien XT
  • Corevalve
  • Acurate-TA
Aortic Valve Replacement
All consecutive patients aged ≥ 80 years or with Logistic Euroscore≥ 15% undergoing AVR for AS at participating centers during the period of enrollment
Surgical AVR, with all kind of commercially available prosthesis (stented, stentless, mechanical)

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Mini Mental State Examination (MMSE)
Tidsramme: baseline, 3-month, 12-month
Changes in cognitive function after transcatheter aortic valve implantation and surgical aortic valve replacement
baseline, 3-month, 12-month
Hospital Anxiety and Depression Scale (HADS)
Tidsramme: baseline, 3-month, 12-month
Changes of emotional status after transcatheter aortic valve implantation and surgical aortic valve replacement
baseline, 3-month, 12-month
Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Tidsramme: baseline, 3-month, 12-month
Changes in quality of life after transcatheter aortic valve implantation and surgical aortic valve replacement
baseline, 3-month, 12-month
In-hospital costs
Tidsramme: Participants will be followed for the duration of hospital stay, an expected average of 10 days for transcatheter aortic valve implantation and 2 weeks for surgical Aortic Valve Replacement
Calculation of precise hospital costs for transcatheter aortic valve implantation and surgical Aortic Valve Replacement, including costs of hospitalization, drugs and devices.
Participants will be followed for the duration of hospital stay, an expected average of 10 days for transcatheter aortic valve implantation and 2 weeks for surgical Aortic Valve Replacement

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Myocardial infarction
Tidsramme: 30-day, 12-month and up to 2-year (longest available follow-up)
Incidence of myocardial infarction
30-day, 12-month and up to 2-year (longest available follow-up)
Stroke
Tidsramme: 30-day, 12-month and up to 2-year (longest available follow-up)
Incidence of stroke
30-day, 12-month and up to 2-year (longest available follow-up)
Pace-maker implantation
Tidsramme: 30-day, 12-month
Need for permanent pacing
30-day, 12-month
Vascular complications
Tidsramme: 30-day
Incidence of vascular complications as defined by the VARC
30-day
Bleedings
Tidsramme: 30-day
Incidence of bleedings as defined by the VARC
30-day
Acute kidney injury
Tidsramme: 30-day
Incidence of AKI as defined by the VARC
30-day
Follow-up costs
Tidsramme: 12-month
Evaluation of costs during follow-up, including new hospital admissions, outpatient clinic and drugs
12-month

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. desember 2011

Primær fullføring (Faktiske)

1. januar 2016

Studiet fullført (Faktiske)

1. januar 2016

Datoer for studieregistrering

Først innsendt

8. mai 2013

Først innsendt som oppfylte QC-kriteriene

9. mai 2013

Først lagt ut (Anslag)

13. mai 2013

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

15. november 2016

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2016

Sist bekreftet

1. november 2016

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere